Oxaliplatin/rituximab combination in the treatment of intermediate-low grade non-Hodgkin's lymphoma of elderly patients

Oncology Reports

Volumn 12, Issue 1, 2004, Pages 135-140

  Addeo, Raffaele ^a   Caraglia, Michele ^a,b   Costanzo, Raffaele ^a   Faiola, Vincenzo ^a   Montella, Liliana ^a   Abbruzzese, Alberto ^b   Del Prete, Salvatore ^a  

^a SAN GIOVANNI DI DIO HOSPITAL   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Elderly; Non Hodgkin's lymphoma; Oxaliplatin; Quality of life; Rituximab

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; OXALIPLATIN; PLATINUM COMPLEX; RITUXIMAB;

AGED; ARTICLE; CANCER STAGING; CLINICAL TRIAL; DRUG ADMINISTRATION; FEASIBILITY STUDY; FEMALE; HUMAN; MALE; NONHODGKIN LYMPHOMA; PATHOLOGY; PHASE 2 CLINICAL TRIAL;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS;

EID: 20444440131     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.12.1.135     Document Type: Article

References (32)

1. Reiser M and Diehl V: Current treatment of follicular non- Hodgkin's lymphoma. Eur J Cancer 38: 1167-1172, 2002. (Pubitemid 34603475)
2. Dillman RO: Treatment of low-grade B-cell lymphoma with the monoclonal antibody rituximab. Semin Oncol 30: 434-447, 2003.
3. Bertini M, Boccomini C and Calvi R: The influence of advanced age on the treatment and prognosis of diffuse largecell lymphoma (DLCL). Clin Lymphoma 1: 278-284, 2001. (Pubitemid 32331683)
4. Plosker GL and Figgitt DP: Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 63: 803-843, 2003. (Pubitemid 36432084)
5. Coiffier B: Immunochemotherapy: the new standard in aggressive non-Hodgkin's lymphoma in the elderly. Semin Oncol 30: 21-27, 2003.
6. Avivi I, Robinson S and Goldstone A: Clinical use of rituximab in haematological malignancies. Br J Cancer 89: 1389-1394, 2003. (Pubitemid 37390853)
7. Maloney DG, Smith B and Rose A: Rituximab: mechanism of action and resistance. Semin Oncol 29: 2-9, 2002. (Pubitemid 34171789)
8. Colombat P, Salles G, Brousse N, et al: Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 97: 101-106, 2001. (Pubitemid 32061248)
9. Coiffier B, Lepage E, Briere J, et al: First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma. Semin Oncol 30 (Suppl 2): 9-16, 2003.
10. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346: 235-242, 2002. (Pubitemid 34438862)
11. Velasquez WS, Cabanillas F, Salvador P, et al: Effective salvage therapy for lymphoma with cisplatin in combination with highdose Ara-C and dexamethasone (DHAP). Blood 71: 117-122, 1988. (Pubitemid 18050400)
12. Velasquez WS, McLaughlin P, Tucker S, et al: ESHAP - an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 12: 1169-1176, 1994. (Pubitemid 24173930)
13. Hickish T, Roldan A, Cunningham D, et al: EPIC: an effective low toxicity regimen for relapsing lymphoma. Br J Cancer 68: 599-604, 1993. (Pubitemid 23258469)
14. Rodriguez-Monge EJ and Cabanillas F: Long-term follow-up of platinum-based lymphoma salvage regimens. The M.D. Anderson Cancer Center experience. Hematol Oncol Clin North Am 11: 937-947, 1997. (Pubitemid 27431154)
15. Raymond E, Faivre S, Woynarowski JM and Chaney SG: Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 25: 4-12, 1998. (Pubitemid 28248696)
16. Rixe O, Ortuzar W, Alvarez M, et al: Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 52: 1855-1865, 1996. (Pubitemid 26419675)
17. De Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947, 2000. (Pubitemid 30644117)
18. Giacchetti S, Perpoint B, Zidani R, et al: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18: 136-147, 2000. (Pubitemid 30036347)
19. Chollet P, Bensmaine MA, Brienza S, et al: Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol 7: 1065-1070, 1996. (Pubitemid 27050831)
20. Soulie P, Bensmaine A, Garrino C, et al: Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer. Eur J Cancer 33: 1400-1406, 1997. (Pubitemid 27404897)
21. Faivre S, Kalla S, Cvitkovic E, et al: Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: an investigator originated compassionate-use experience. Ann Oncol 10: 1125-1128, 1999. (Pubitemid 29482472)
22. Piccart MJ, Green JA, Lacave AJ, et al: Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. J Clin Oncol 18: 1193-1202, 2000. (Pubitemid 30159836)
23. Monnet I, Brienza S, Hugret F, et al: Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC). ATTIT. Association pour le traitement des tumeurs intra thoraciques. Eur J Cancer 34: 1124-1127, 1998. (Pubitemid 28308357)
24. Soulie P, Garrino C, Bensmaine MA, et al: Antitumoral activity of oxaliplatin/cisplatin-based combination therapy in cisplatinrefractory germ cell cancer patients. J Cancer Res Clin Oncol 125:707-711, 1999.
25. Chollet P, Bensmaine MA, Brienza S, Deloche C, Cure H and Caillet H: Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol 7: 1065-1070, 1996. (Pubitemid 27050831)
26. Machover D, Diaz-Rubio E, de Gramont A, et al: Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 7: 95-98, 1996. (Pubitemid 26051870)
27. Becouarn Y, Ychou M, Ducreux M, et al: Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J Clin Oncol 16: 2739-2744, 1998. (Pubitemid 28363039)
28. Diaz-Rubio E, Sastre J, Zaniboni A, et al: Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. Ann Oncol 9: 105-108, 1998. (Pubitemid 28125772)
29. Germann N, Brienza S, Rotarski M, et al: Preliminary results on the activity of oxaliplatin (L-OHP) in refractory/recurrent non- Hodgkin's lymphoma patients. Ann Oncol 10: 351-354, 1999. (Pubitemid 29217229)
30. Chau I, Webb A, Cunningham D, et al: An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma. Br J Haematol 115: 786-792,2001. (Pubitemid 34042894)
31. Harris NL, Jaffe ES, Stein H, et al: A revised European- American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84: 1361-1392, 1994. (Pubitemid 24273002)
32. Cella DF, Tulsky DS, Gray G, et al: The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 11: 570-579, 1993. (Pubitemid 23071057)